Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125272241 | 12527224 | 1 | I | 20160531 | 20160705 | 20160705 | EXP | US-ELI_LILLY_AND_COMPANY-US201606001194 | ELI LILLY AND CO | 0.00 | F | Y | 81.63000 | KG | 20160704 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125272241 | 12527224 | 1 | PS | ADCIRCA | TADALAFIL | 1 | Unknown | U | 21368 | TABLET | |||||||||
| 125272241 | 12527224 | 2 | SS | TYVASO | TREPROSTINIL | 1 | Respiratory (inhalation) | 9-12 BREATHS, QID | U | 2100765 | 0 | QID | |||||||
| 125272241 | 12527224 | 3 | C | LETAIRIS | AMBRISENTAN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125272241 | 12527224 | 1 | Product used for unknown indication |
| 125272241 | 12527224 | 2 | Pulmonary hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125272241 | 12527224 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125272241 | 12527224 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125272241 | 12527224 | 2 | 20120801 | 0 |